Mink Therapeutics Inc

Company Profile

Mink Therapeutics Inc had its IPO on 2021-10-15 under the ticker symbol INKT.

The company operates in the Healthcare sector and Biotechnology industry. Mink Therapeutics Inc has a staff strength of 37 employees.

Stock update

Shares of Mink Therapeutics Inc opened at $1.28 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.26 - $1.35, and closed at $1.32.

This is a +2.33% increase from the previous day's closing price.

A total volume of 42,922 shares were traded at the close of the day’s session.

In the last one week, shares of Mink Therapeutics Inc have slipped by -9.59%.

Mink Therapeutics Inc's Key Ratios

Mink Therapeutics Inc has a market cap of $50.38 million, indicating a price to book ratio of 11.5018 and a price to sales ratio of 0.

In the last 12-months Mink Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-27910044. The EBITDA ratio measures Mink Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Mink Therapeutics Inc’s operating margin was 0% while its return on assets stood at -81.18% with a return of equity of -1238.98%.

In Q2, Mink Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Mink Therapeutics Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-0.8 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Mink Therapeutics Inc’s profitability.

Mink Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -3.7022. Its price to sales ratio in the trailing 12-months stood at 0.

Mink Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$12.11 million

Total Liabilities

$11.46 million

Operating Cash Flow

$0

Capital Expenditure

$37018

Dividend Payout Ratio

0%

Mink Therapeutics Inc ended 2024 with $12.11 million in total assets and $0 in total liabilities. Its intangible assets were valued at $12.11 million while shareholder equity stood at $-9495364.00.

Mink Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $11.46 million in other current liabilities, 345.00 in common stock, $-122822070.00 in retained earnings and $0 in goodwill. Its cash balance stood at $10.62 million and cash and short-term investments were $10.62 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Mink Therapeutics Inc’s total current assets stands at $11.05 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $4.89 million and inventory worth $0.

In 2024, Mink Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $37018.

Comparatively, Mink Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$1.32

52-Week High

$3.42

52-Week Low

$0.851

Analyst Target Price

$8.33

Mink Therapeutics Inc stock is currently trading at $1.32 per share. It touched a 52-week high of $3.42 and a 52-week low of $3.42. Analysts tracking the stock have a 12-month average target price of $8.33.

Its 50-day moving average was $1.72 and 200-day moving average was $2.04 The short ratio stood at 2.95 indicating a short percent outstanding of 0%.

Around 7176.6% of the company’s stock are held by insiders while 174.9% are held by institutions.